Literature DB >> 33794192

CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism.

Hyelim Cho1, Qiong Shen1, Lydia H Zhang2, Mikiko Okumura2, Akinori Kawakami3, Jessi Ambrose1, Frederic Sigoillot1, Howard R Miller1, Scott Gleim1, Amanda Cobos-Correa4, Ying Wang4, Philippe Piechon4, Guglielmo Roma4, Fabian Eggimann4, Charles Moore4, Peter Aspesi1, Felipa A Mapa1, Heather Burks1, Nathan T Ross1, Philipp Krastel4, Marc Hild1, Thomas J Maimone2, David E Fisher3, Daniel K Nomura5, John A Tallarico6, Stephen M Canham6, Jeremy L Jenkins7, William C Forrester8.   

Abstract

Three limonoid natural products with selective anti-proliferative activity against BRAF(V600E) and NRAS(Q61K)-mutation-dependent melanoma cell lines were identified. Differential transcriptome analysis revealed dependency of compound activity on expression of the mitochondrial cytochrome P450 oxidase CYP27A1, a transcriptional target of melanogenesis-associated transcription factor (MITF). We determined that CYP27A1 activity is necessary for the generation of a reactive metabolite that proceeds to inhibit cellular proliferation. A genome-wide small interfering RNA screen in combination with chemical proteomics experiments revealed gene-drug functional epistasis, suggesting that these compounds target mitochondrial biogenesis and inhibit tumor bioenergetics through a covalent mechanism. Our work suggests a strategy for melanoma-specific targeting by exploiting the expression of MITF target gene CYP27A1 and inhibiting mitochondrial oxidative phosphorylation in BRAF mutant melanomas.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; CYP27A1; MITF; cancer metabolism; melanoma; mitochondrial complex I; natural products; oncology; oxidative phosphorylation; prodrug

Mesh:

Substances:

Year:  2021        PMID: 33794192      PMCID: PMC8481390          DOI: 10.1016/j.chembiol.2021.03.004

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   9.039


  78 in total

Review 1.  Natural Products as Sources of New Drugs from 1981 to 2014.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2016-02-07       Impact factor: 4.050

2.  Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.

Authors:  Natalia Mast; Joseph B Lin; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2015-06-16       Impact factor: 4.436

3.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

4.  Mitochondrial Hsp70/MIM44 complex facilitates protein import.

Authors:  H C Schneider; J Berthold; M F Bauer; K Dietmeier; B Guiard; M Brunner; W Neupert
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

5.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.

Authors:  Jinyan Du; Arlo J Miller; Hans R Widlund; Martin A Horstmann; Sridhar Ramaswamy; David E Fisher
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

6.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors:  Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

7.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

8.  Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF.

Authors:  L Hou; J J Panthier; H Arnheiter
Journal:  Development       Date:  2000-12       Impact factor: 6.868

9.  Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.

Authors:  Cheryl Carson; Pichai Raman; Jennifer Tullai; Lei Xu; Martin Henault; Emily Thomas; Sarita Yeola; Jianmin Lao; Mark McPate; J Martin Verkuyl; George Marsh; Jason Sarber; Adam Amaral; Scott Bailey; Danuta Lubicka; Helen Pham; Nicolette Miranda; Jian Ding; Hai-Ming Tang; Haisong Ju; Pamela Tranter; Nan Ji; Philipp Krastel; Rishi K Jain; Andrew M Schumacher; Joseph J Loureiro; Elizabeth George; Giuliano Berellini; Nathan T Ross; Simon M Bushell; Gül Erdemli; Jonathan M Solomon
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

10.  Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells.

Authors:  Franziska Baenke; Barbara Chaneton; Matthew Smith; Niels Van Den Broek; Kate Hogan; Haoran Tang; Amaya Viros; Matthew Martin; Laura Galbraith; Maria R Girotti; Nathalie Dhomen; Eyal Gottlieb; Richard Marais
Journal:  Mol Oncol       Date:  2015-08-20       Impact factor: 6.603

View more
  4 in total

Review 1.  Inverse Drug Discovery identifies weak electrophiles affording protein conjugates.

Authors:  Gabriel M Kline; Karina Nugroho; Jeffery W Kelly
Journal:  Curr Opin Chem Biol       Date:  2022-01-20       Impact factor: 8.822

2.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

3.  Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.

Authors:  Sipeng Zuo; Huixue Wang; Lin Li; Hui Pan; Linna Lu
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

4.  In Vitro Antimelanoma Properties of Verbena officinalis Fractions.

Authors:  Rabia Nisar; Sanjay Adhikary; Saeed Ahmad; Mohammad Abrar Alam
Journal:  Molecules       Date:  2022-09-26       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.